AngioDynamics, Inc. filings document regulatory disclosures for a Nasdaq-listed medical technology company focused on vascular disease, thrombectomy, oncology and surgical device markets. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, and forward-looking statement language tied to product strategy, competitive position, cash flows and operating plans.
The filing record also covers governance and material-event disclosures, including annual meeting voting results, director elections, auditor ratification, advisory executive-compensation votes, executive transition and retirement arrangements, and patent-enforcement litigation involving the company’s thrombectomy intellectual property and self-expanding funnel technology. Proxy materials provide compensation tables, board matters and shareholder-vote mechanics.
Kevin Kotler has filed a Schedule 13G reporting beneficial ownership of 2,421,526 shares of AngioDynamics, Inc. common stock, representing 5.9% of the class as of 01/06/2026. He holds sole voting and dispositive power over these shares and reports the stake as passive, not for influencing control.
The filing notes that 313,495 shares are owned in his individual capacity, while the remainder is held in accounts he manages. He also formally disclaims beneficial ownership beyond his pecuniary interest in the reported securities.
AngioDynamics outlined a planned leadership transition and retention program for senior executives. President and CEO James C. Clemmer signed a Transition and Retirement Agreement under which he will continue as CEO until a successor is appointed or until November 30, 2026, with possible month‑to‑month extensions by mutual agreement. His existing stock options and service-based restricted stock units will continue to vest until his service as a consultant or director ends, after which they immediately vest, while performance-based restricted stock units may still vest according to their original terms. The board also approved retention agreements for the executive leadership team: key named executive officers are eligible for cash retention awards equal to 150% of base salary and others for 50% of base salary, if they remain employed until the earlier of six months after the new CEO starts or June 1, 2027.
AngioDynamics, Inc. filed a current report after its President and CEO, James Clemmer, presented at the J.P. Morgan 44th Annual Healthcare Conference on January 14, 2026. The company has made the conference presentation slides available as Exhibit 99.1, furnishing them for informational purposes.
The report clarifies that these slides are furnished rather than filed, meaning they are not subject to certain liability provisions and are not automatically incorporated into other securities filings. It also includes a detailed caution about forward-looking statements, noting that expectations about strategy, products, financial position and growth are subject to numerous risks, including regulatory actions, economic conditions, competition, supply chain challenges and factors described in prior AngioDynamics SEC reports.
AngioDynamics, Inc. received an updated large-shareholder disclosure showing that investment entities affiliated with Millennium reported modest, passive stakes in its common stock. Integrated Core Strategies (US) LLC reported beneficial ownership of 551,565 shares, representing 1.3% of AngioDynamics’ common stock. Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported beneficial ownership of 842,548 shares, or 2.0% of the outstanding common stock, as of the event date of 12/31/2025. The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of AngioDynamics.
AngioDynamics, Inc. reported stockholder voting results. Shareholders elected two directors: James C. Clemmer received 29,634,152 votes for and 800,454 withheld, with 5,462,943 broker non-votes; Michael E. Tarnoff, MD received 29,245,896 votes for and 1,188,710 withheld, with 5,462,943 broker non-votes.
Stockholders also approved two additional items. One item received 35,727,186 votes for, 156,899 against, and 13,464 abstentions; there were no broker non-votes for this item. Another item received 28,357,782 votes for, 2,057,982 against, 18,842 abstentions, and 5,462,943 broker non-votes.
AngioDynamics (ANGO) reported an insider open‑market purchase. On 10/21/2025, an officer serving as SVP, Chief Legal Officer bought 10,000 shares of common stock, coded “P” for purchase. The weighted average price was $11.81, with trades executed between $11.71 and $11.90. After this transaction, the reporting person beneficially owned 93,597 shares, held directly. The filing notes the weighted‑average pricing and that detailed trade‑by‑trade data within the price range is available upon request.
AngioDynamics, Inc. filed a Form S-8 to register 4,700,000 shares of common stock for issuance under its 2020 Equity Incentive Plan, as approved by shareholders on November 14, 2023 and November 12, 2024.
The filing also includes a Reoffer Prospectus covering the potential resale, from time to time, of up to 2,529,068 shares by certain employees and officers who acquired awards under the plan. The company will receive no proceeds from sales by the selling stockholders, while bearing registration expenses. AngioDynamics’ common stock trades on Nasdaq as “ANGO,” and the last reported sale price was $11.82 per share on October 20, 2025.
Shares outstanding were 41,076,119 as of September 18, 2025; this is a baseline figure, not the amount being registered or resold.
AngioDynamics (ANGO) reported insider activity by its EVP and CFO. A Form 4 shows a purchase of 890 shares of common stock on 10/13/2025 at a price of $11.16 per share, coded “P” for a purchase.
Following the transaction, the reporting person beneficially owns 256,629 shares, held directly. The filing indicates the role as EVP and CFO and confirms the report was filed by one reporting person.
James C. Clemmer, President, CEO and a director of AngioDynamics, Inc. (ANGO), reported an insider purchase of common stock on 10/09/2025. The filing shows a purchase of 10,000 shares at a weighted average price of $11.15, with trade prices in the range $11.10 to $11.17. After the transaction the reporting person beneficially owns 882,529 shares.
The filing is a standard Section 16 Form 4 disclosing a direct purchase by the reporting person. The filer notes the purchase occurred in multiple transactions and offers to provide a breakdown of quantities by price on request. No derivative transactions or dispositions are reported.
AngioDynamics Inc. reported first-quarter fiscal 2026 net sales of $75.7 million, up 12.2% from the prior-year quarter, driven by Med Tech growth of 26.1% (Auryon, NanoKnife, thrombus management) and modest Med Device growth of 2.3%. Gross margin rose 90 basis points to 55.3%. The company recorded a net loss of $10.9 million (loss per share $0.26), an improvement from a $12.8 million loss a year earlier.
The company continues restructuring actions with $2.3 million in charges this quarter and $25.6 million total recorded to date. A settlement with BD (Becton, Dickinson) includes a one-time lump-sum structure and ongoing minimum annual payments; $2.5 million was paid this quarter and a contingent $3.0 million may be due depending on the Federal Circuit appeal (oral argument set for October 8, 2025). Management maintains a valuation allowance on deferred tax assets and noted continued macroeconomic and supply-chain risks. The company has a $25.0 million revolving credit facility with $0 drawn as of August 31, 2025.